04 May 2016
(Journal 6624)
| SPC/GB11/043 | Withdrawn | Applicants: GlaxoSmithKline Biologicals S.A. and GlaxoSmithKline Biologicals, Niederlassung der SmithKline Beecham Rue de l'Institute 89, 0-1330 Rixensart, Belgium
Product: An adjuvanted influenza vaccine comprising an influenza virus component which is an influenza virus antigen from an influenza virus strain that is associated with a pandemic outbreak or has the potential to be associated with a pandemic outbreak, wherein
Product Type: Medicinal Authorised: UK EU/1/08/453/001 14 May 2008
Authorised Extension:
Patent No: EP1618889 Title: Influenza vaccine
SPC No: SPC/GB11/043 Date Lodged: 18 August 2011 |